Journal
CURRENT OPINION IN VIROLOGY
Volume 11, Issue -, Pages 148-157Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2015.04.001
Keywords
-
Categories
Funding
- NIH [R01 AI079031, R01 AI084817, R01 AI106005]
- Skaggs Institute for Chemical Biology at The Scripps Research Institute
Ask authors/readers for more resources
Hepatitis C virus infects nearly 3% of the world's population and is often referred as a silent epidemic. It is a leading cause of liver cirrhosis and hepatocellular carcinoma in endemic countries. Although antiviral drugs are now available, they are not readily accessible to marginalized social groups and developing nations that are disproportionally impacted by HCV. To stop the HCV pandemic, a vaccine is needed. Recent advances in HCV research have provided new opportunities for studying HCV neutralizing antibodies and their subsequent use for rational vaccine design. It is now recognized that neutralizing antibodies to conserved antigenic sites of the virus can cross-neutralize diverse HCV genotypes and protect against infection in vivo. Structural characterization of the neutralizing epitopes has provided valuable information for design of candidate immunogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available